Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12611MR)

This product GTTS-WQ12611MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer, Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12611MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5132MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ15325MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ8294MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ8326MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ15198MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ7113MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ5051MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW